Press Releases

Back
  • A transdisciplinary approach with bio-nanodevice interfaces / 2019

    GLADIATOR - New technologies for cancer monitoring and therapy

    Press Release / 3.6.2019

    The Fraunhofer Institute for Biomedical Engineering IBMT is contributing its expertise in the field of medical biotechnology and ultrasound to a new EC project to work on the next generation of theranostics for brain pathologies using autonomous externally controllable nanonetworks.

    more info
  • © Fraunhofer IBMT, Photo: Bernd Müller.

    Application-specific high-throughput stem cell production processes revolutionize industrial new drug testing. For biotechnological and pharmaceutical companies, the development of cell culture automation using innovative materials is a promising approach to optimize existing processes. By customized material characteristics, expansion and/or differentiation of human stem cells (with focus on human induced pluripotent stem cells, hiPSCs) shall be positively influenced and automated solutions for the production for high-qualitative cells shall be developed. These generated cells can then be used for the production of model systems for drug tests, toxicity studies or disease modelling, thus providing e. g., a major contribution to personalized medicine or the avoidance of animal experiments.

    more info
  • © Fraunhofer IBMT, Bernd Müller.

    Together, the Fraunhofer Institute for Biomedical Engineering IBMT, the Fraunhofer Institute for Applied Information Technology FIT and the Fraunhofer Project Center for Stem Cell Process Engineering SPT present selected topics of laboratory technology and biotechnology in the mobile epidemiological BSL2 laboratory, the so-called »mobile EpiLab«.

    more info
  • EBiSC2 will secure long-term access to well characterised and quality-controlled hiPSCs for academic and commercial researchers worldwide, continuing to support R&D activities such as disease modelling and drug discovery.

    more info
  • Project network provides innovative IT platform for clinical data integration, model development and validation / 2019

    Personalized Medicine: Effective through Artificial Intelligence in Transplantation Medicine - New Prediction Models for Disease Progression Developed

    Press Release / 5.3.2019

    © AdobeStock_126446055

    If radiation or chemotherapy treatment of leukaemias or lymphomas does not bring sufficient success, the transplantation of bone marrow or blood stem cells is usually the only chance of cure. Unfortunately, the majority of patients die despite transplantation, often due to spontaneous infections, transplant versus recipient reactions and recurrences. New predictive models for the individual course of disease, as developed in the "XplOit" research project, predict the occurrence and extent of these risks and thus enable transplantation physicians to intervene at an early stage to save lives in dreaded complications.

    more info
  • Laboratories of the Main Department Medical Biotechnology of the Fraunhofer Institute for Biomedical Engineering IBMT certified and accredited / 2019

    Committed to the Highest Quality

    Press Release / 1.3.2019

    Since mid-February 2019, the laboratories of the Main Department of Medical Biotechnology in Sulzbach are now also GLP certified. In Saarland, the Ministry of the Environment and Consumer Protection is responsible for issuing a GLP certificate in accordance with § 19b (1) of the Chemicals Act.

    more info
  • Fraunhofer IBMT at MEDICA 2018 / 2018

    Treating the fear of spiders with augmented reality

    Press Release / 7.11.2018

    Arachnophobia is the technical term for the fear of spiders. Approximately 3.5 to 6.1 percent of the population suffer from this phobia. Exposure therapy is the most common form of treatment. However, 60 to 80 percent of arachnophobes do not receive any therapy because of a lack of services. Others simply cannot bear the terror of facing up to real spiders. Together with partners, Fraunhofer researchers are developing a digital therapy system that is designed to facilitate treatment in the home environment and give sufferers a better sense of security. A demonstrator of the system will be exhibited at the MEDICA trade fair in Düsseldorf from November 12 to 15 (Hall 10, Booth G05/H04).

    more info
  • Fraunhofer IBMT at MEDICA 2018: Treating amblyopia in children / 2018

    Interactive shutter eyeglasses to replace eyepatch therapy

    Press Release / 7.11.2018

    The standard treatment for so-called lazy eye (amblyopia) in children is to cover the nonimpaired eye with a patch. This trains the impaired eye to work harder. Such therapy is successful only when the patient wears the eyepatch for the prescribed period of time. This is often not the case, however, as many children feel self-conscious about wearing the patch and reject this form of treatment. A future alternative is electronic shutter eyeglasses that automatically darken the lens in front of the nonimpaired eye when the context is appropriate. These eyeglasses also have integrated sensors that provide young wearers with feedback on whether they are being worn in the correct position. Fraunhofer researchers will be exhibiting a functional model of the electronic shutter eyeglasses at the MEDICA trade fair in Düsseldorf from November 12 to 15 (Hall 10, Booth G05/H04).

    more info